Renin–angiotensin-aldosterone system (RAAS) inhibitors are thought to be capable of reducing the left ventricular afterload in AS patients, thereby alleviating myocardial hypertrophy and fibrosis [32]. The gene discussed is REN; the disease is cardiac hypertrophy.